OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles

Regulatory News:

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced the departure of Alexis Peyroles as Chief Executive Officer. Dominique Costantini, current Chairwoman of OSE Immunotherapeutics’ Board of Directors, and previously CEO from 2012 to 2018, has been appointed interim Chief Executive Officer, effective immediately. A search for a new CEO has been launched with the assistance of a leading executive search firm.

Alexis Peyroles is stepping down for health reasons and he remains committed to OSE’s success. He will continue to support the company in a consulting capacity for the upcoming months to ensure a smooth transition.

During this transition period, Dominique Costantini will rely on OSE’s reinforced leadership team, including notably Laurence de Schoulepnikoff, today Chief Business Officer, appointed as Chief Operating Officer of the Company, functions which she previously held at AMAL Therapeutics.

Dominique Costantini, Chairwoman and Chief Executive Officer of OSE Immunotherapeutics, said: “We thank Alexis for his strong involvement and wish him the very best. Thanks to Alexis’s leadership, as company COO since OSE’s early days and then as CEO since 2018, OSE became a significant player in immunology & inflammation and immuno-oncology. Three major pharma partnering agreements were signed, a diversified pipeline of best and first-in-class products was built, and a very strong team has been set up. Alexis will continue to support the company as an advisor to ensure the best transition possible.”

Dominique Costantini added: “I warmly thank the Board of Directors for their trust as we are entering a new phase of growth, a transformative time focused on advancing our innovative clinical and preclinical assets in immunology & inflammation and immuno-oncology. We are committed to ensuring a successful evolution in recruiting the best candidate to lead this next step for OSE.”

ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile: